Changes in Hong Kong stocks | Rongchang Biotech (09995) rose more than 6% intraday, and titacipr was included in the 2026 National Essential Drug List as an “immune system drug”

The Zhitong Finance App learned that Rongchang Biotech (09995) rose more than 6% in the intraday period. As of press release, it had risen 6.16% to HK$87, with a turnover of HK$268 million.

According to news, according to Rongchang Biotech's official Weibo, on July 9, three departments of the National Health Commission, the State Administration of Traditional Chinese Medicine, and the State Administration for Disease Control and Prevention jointly released the “National Essential Drug Catalogue (2026 Edition)”. Tetasip (sterile powder for injection: 80mg), the world's first novel dual-target fusion protein drug independently developed by the company, was included in the “immune system medication” in the catalogue. A total of 2 domestically produced Class I bioinnovative drugs are included in the new catalogue. Taytacip is one of them.

As one of the 2 domestically produced Class 1 bioinnovative drugs included in the essential drug catalogue this time, with its world-first dual-target mechanism, it can treat a series of B-cell-mediated autoimmune diseases by simultaneously inhibiting excessive expression of BLYS and April. It has been approved successively for 5 indications, including systemic lupus erythematosus, rheumatoid arthritis, systemic myasthenia gravis, dry syndrome, and IgA nephropathy (pre-filled injections). Among them, systemic lupus erythematosus and systemic myasthenia gravis have been included in the national medical insurance catalogue..